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Aim.t oc o m p a r e18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) to sentinel lymph node biopsy (SLNB) for
regional lymph nodal staging in patients with melanoma. Methods. We performed a literature review discussing original articles
which compared FDG-PET to SLNB for regional lymph nodal staging in patients with melanoma. Results and Conclusions.T h e r e
is consensus in the literature that FDG-PET cannot replace SLNB for regional lymph nodal staging in patients with melanoma.
1.Introduction
Theusefulnessofimaging studiesin patientswithmelanoma
generally depends on the stage of the tumour. In patients
with early-stage disease, surgery is often curative with little
role for comprehensive imaging in this patient population
[1].
Regionallymphnodesarethemostfrequentsiteofmeta-
static disease. In many patients with primary cutaneous mel-
anoma and clinically negative regional lymph nodes, surgical
staging of the regional nodal basins at risk is performed us-
ing intraoperative lymphatic mapping and sentinel lymph
node biopsy (SLNB). Regional nodal basins at risk (sentinel
lymph nodes (SLN)) are typically identiﬁed by preoperative
lymphoscintigraphy (LS) using intradermal injection of
technetium-labelled sulphur colloid around the primary
melanoma [2, 3].
Positronemissiontomographywith 18F-Fluorodeoxyglu-
cose(FDG-PET)isafunctionalnoninvasiveimagingmethod
extensively investigated in patients with melanoma [3].
We searched in the literature for relevant published arti-
cles which compared FDG-PET to SLNB for regional lymph
nodal staging in patients with melanoma in order to assess if
FDG-PET could substitute SLNB in this setting.
2. ComparisonbetweenFDG-PETandSLNBfor
Regional Lymph Nodal Stagingin
Patients withMelanoma: LiteratureData
Theﬁrststudyonthistopicwaspublishedin1999byWagner
et al. [4], who compared FDG-PET imaging of regional
lymph node basins to SLNB, in patients with American
Joint Committee on Cancer (AJCC) stages I, II, and III
melanoma. Seventy patients with cutaneous melanoma with
Breslow thickness greater than 1mm (AJCC T2-4N0M0) or
localized regional cutaneous recurrence (TxN2bM0) under-
went whole-body FDG-PET followed by SLNB. Eighty-nine
lymph node basins were evaluated by FDG-PET and SLNB.
Eighteen patients (25.7%) had lymph nodal metastases at
the time of FDG-PET imaging: 17 proved by SLNB (24.3%)2 Radiology Research and Practice
and one by follow-up examination (1.4%). Median tumour
volumeinpositiveSLNwas4.3mm3 (range:0.07–523mm3).
Sensitivity of SLNB for detection of occult regional lymph
node metastases was 94.4%, speciﬁcity was 100%, positive
predictive value (PPV) was 100%, and negative predictive
value (NPV) was 98.6%. Sensitivity of FDG-PET was 16.7%,
speciﬁcity was 95.8%, PPV was 50%, and NPV was 81.9%.
FDG-PET predicted one recurrence (14.3%) in a node basin
missed by SLNB. The authors concluded that: (1) FDG-PET
is an insensitive indicator of occult regional lymph node
metastases in patients with melanoma because of the minute
tumour volumes in this population; (2) FDG-PET has not a
primaryroleforstagingregionalnodesinpatientswithAJCC
stage I, II, or III melanoma [4].
Diﬀerent results were reported by Klein et al. [5], who
in 2000 investigated the use of whole-body FDG-PET in
conjunction with LS for evaluating the status of SLNs in
primary melanoma. A subgroup of 17 patients with primary
cutaneous melanoma underwent LS, whole-body FDG-PET
andSLNdissection.Outof20SLNsidentiﬁedbyLSinthe17
patients, 18 were negative on FDG-PET and 2 were positive;
19/20 PET ﬁndings were conﬁrmed either by histopathology
or by clinical followup (20 months). The accuracy of FDG-
PET for the assessment of the status of the SLN was 94%.
From this study, FDG-PET resulted in a reliable non-invasive
alternative to surgery in the characterization of SLN [5].
In 2001, Acland et al. [6] compared the sensitivity of
FDG-PET with SLNB in the detection of micrometastatic
malignant melanoma. Fifty consecutive patients with pri-
mary melanoma (with thickness >1mm or lymphatic inva-
sion) underwent FDG-PET scanning followed by SLNB after
preoperative LS. The SLN was identiﬁed in all patients; all
patients with positive SLNB underwent therapeutic lymph
node dissection. Fourteen patients had positive SLNB but in
none of them FDG-PET identiﬁed metastatic disease in the
SLN or draining basin. This study demonstrated the limita-
tions of FDG-PET scanning in staging patients with primary
melanoma. The authors concluded that SLNB has the disad-
vantage of being an invasive surgical procedure, but it is the
only reliable method for identifying micrometastatic disease
in the regional draining node with high sensitivity [6].
In 2002, Belhocine et al. [7] assessed the value of FDG-
PET for detecting SLN metastases in 21 patients with early-
stage melanoma (AJCC stage I or II) who also underwent
lymphaticmappingandSLNB.Sixofthe21patients(28.5%)
had an involved SLN. PET was positive in only one case
with a SLN >1cm. In the ﬁve other cases, the SLNs missed
by PET were <1cm with focal and/or partial involvements.
One patient, free of regional nodal metastases in both
SLN detection and PET imaging, had, however, a same-
basin recurrence 3 months later. In another case, FDG-
PET had one false positive result. Overall, the detection
of subclinical nodal metastases by SLNB had a sensitivity
of 86%. FDG-PET detected only 14% of SLN metastases.
This study showed that SLNB remains the procedure of
choice for detecting subclinical lymph node involvement
from primary cutaneous melanoma. Owing to its limited
spatial resolution, FDG-PET appears insuﬃciently sensitive
to identify microscopic nodal metastases. As a practical con-
sequence, FDG-PET imaging is not recommended as a ﬁrst-
line imaging strategy for staging regional lymph nodes in
patients with AJCC stage I or II melanoma [7].
In 2003, Havenga et al. [8] reported the value of SLNB
and FDG-PET in staging primary cutaneous melanoma. Fif-
ty-ﬁve patients with primary cutaneous melanoma (with
>1mm Breslow thickness and no palpable regional lymph
nodes) underwent FDG-PET andSLNB.SLNswereretrieved
in 53 patients. Melanoma metastases were found in the SLN
of 13 patients, but in only two of these 13 patients the lymph
node metastases were detected by FDG-PET. Conversely, in
ﬁve patients FDG uptake was recorded in a regional lymph
node basin, but no tumour-positive SLN was found; no
explanation for the positive FDG-PET result could be found
in these ﬁve cases. The conclusions of this study were that:
(1) FDG-PET should not be considered for staging regional
lymph nodal disease in patients with primary cutaneous
melanoma; (2) SLNB reveals regional metastases that are too
small to be detected by FDG-PET [8].
In the same year, Longo et al. [9]c o m p a r e dF D G - P E T
imaging to SLNB for primary identiﬁcation of lymph node
involvement in patients with clinical staging I and II of
cutaneous melanoma. Twenty-ﬁve patients with cutaneous
melanoma (with a Breslow thickness equal or greater to
1mm) underwent a preoperative FDG-PET to assess lymph
node involvement. SLNB and FDG-PET showed a sensitivity
of 100% and 22%, respectively, in the identiﬁcation of lymph
node metastases. The authors conﬁrmed that FDG-PET is
not a sensitive technique for the initial staging of patients
with melanoma localized to the skin. The technique may
nevertheless have a role for patients in whom SLNB is
not indicated such as patients with a high surgical risk or
those with prior wide local excisions that disrupt lymphatic
drainage rendering SLNB less reliable [9].
In their study, Sch¨ afer et al. [10] evaluated SLNB and
FDG-PET in the staging of 51 melanoma patients (stages
I and II according to the guidelines of the German Der-
matological Society). Tumor thickness ranged from 1.0mm
to 6.0mm. At least one SLN was excised in all patients; 80
SLNswereexcisedfrom69lymphaticdrainageareas.Positive
SLNsweredetectedin6patients(11.8%).Additionalpositive
lymph nodes were not detected in any of these patients in
the following lymph node dissection of the aﬀected lymph
node basin. Preoperative FDG-PET was performed in 40
patients and did not detect any of the micrometastases that
were subsequently found by SLNB. During the followup of
7–40 months (mean 21.9 months), 3 patients experienced
tumor progression; 2 of 3 had a positive SLN. These ﬁnd-
ings demonstrated that: (1) SLNB is recommendable in
melanoma patients with primary tumors greater than 1mm
in thickness; (2) FDG-PET could not be expected to give
additional information in the staging of stage I-II melanoma
[10].
In 2004, Fink et al. [11] compared FDG-PET ﬁndings
with histopathological results of SLNB in order to assess
the value of FDG-PET in predicting regional lymph node
involvement in 48 patients with primary stages I and II mel-
anoma who underwent FDG-PET scans, preoperative LS,
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(16.7%) had a positive SLNB. FDG-PET was positive in
only one patient with a positive SLNB, yielding a sensitivity
of 13%. All other positive SLNs could not be detected by
FDG-PET imaging. This study conﬁrmed that FDG-PET is
not an adequate screening test for subclinical lymph node
metastases in patients with stages I and II melanoma. The
low sensitivity is probably due to the small size of metastatic
deposits in SLN. Therefore, SLNB remains the technique of
choice for evaluating the histological status of lymph node
basinsinpatientswithearly-stagecutaneousmelanoma[11].
In 2004, Hafner et al. [12] evaluated the sensitivity and
speciﬁcity of SLNB and FDG-PET in the early detection of
regional lymph node metastases in patients with melanoma.
Onehundred patientswithmelanomaandBreslowthickness
over 1.0mm were enrolled. SLNB was positive in 26 patients.
FDG-PET detected two of 26 histologically tumour-positive
SLNs (sensitivity 8%; speciﬁcity 100%). At 18-month fol-
lowup, ﬁveof 26 (19%) patients witha positive SLN and four
of 74 (5%) patients with a negative SLN had recurrent or
progressive disease. Ninety percent of tumour-positive SLNs
containedmicrometastaseswithadiameterbelowtheresolu-
tion of PET or US, which has been measured approximately
at 4mm. Therefore, radiological examinations such as US
and PET cannot have a high sensitivity at baseline staging
in patients with melanoma [12].
In 2005, Libberecht et al. [13] retrospectively evaluated
the accuracy of SLNB and FDG-PET for early detection of
lymph node metastases in 5 patients presenting with mel-
anoma without clinical lymph node involvement and a
Breslowthicknessover1mm.InnoneofthepatientsthePET
scan showed signs of lymph node involvement. However,
two patients, both with a Breslow thickness of 1.4mm, had
micrometastases in the SLN which were missed by PET scan-
ning. Therefore, the authors concluded that: (1) FDG-PET
is of limited value in melanoma patients without palpable
lymphnodes;(2)SLNBprovedtobeausefultoolandshould
be considered in the initial staging of melanoma without
palpable lymph node or distant metastases [13].
In the same year, Vereecken et al. [14] evaluated the
pertinence of a preoperative extensive staging procedure,
including morphological and metabolic imaging and SLNB,
in intermediate/high-risk melanoma patients. Forty-three
patients with intermediate/poor prognosis primary mela-
noma beneﬁted from complementary excision and SLNB
after clinical and radiological staging (including FDG-PET
scan). SLNB showed the presence of regional lymph node
metastases in 10 patients, conﬁrmed by the FDG-PET scan
in four cases (sensitivity of FDG-PET: 40%). The authors
conﬁrmed that FDG-PET is not useful to detect lymph nodal
micrometastasis and cannot replace SLNB in initial regional
staging of patients with melanoma [14].
In their prospective study, Wagner et al. [15] determined
the sensitivity and speciﬁcity of initial FDG-PET scan for
detection of occult lymph node metastases in patients with
early-stagecutaneousmelanoma(inclusioncriteria:tumours
with >1mm Breslow thickness, local disease recurrence,
or solitary in-transit metastases without regional lymph
nodal or distant metastases by standard clinical evaluation).
FDG-PET ﬁndings in regional lymph nodes were compared
with histology of SLNB specimens. SLNB and/or followup
demonstrated regional lymph node metastases in 43 of 184
lymph node basins in 40 patients (27.8%). Compared with
all clinical information, FDG-PET sensitivity for detection
of regional lymph node metastases was 21% and speciﬁcity
was 97%. FDG-PET did not impact the care of patients with
early-stage melanoma already staged by standard techniques.
Routine FDG-PET scanning was not recommended for
the initial staging evaluation in this population because it
resulted an insensitive indicator of occult regional lymph
node metastases in patients with early-stage melanoma; it
could not replace surgical techniques such as SLNB for stag-
ing of occult lymph node metastases in this population. The
authors concluded that routine FDG-PET scan staging at the
timeofinitialdiseasepresentationdoesnothaveasigniﬁcant
clinicalimpactinpatientswithstagesIandIImelanomawho
are candidates for lymph node staging with SLNB [15].
In 2006, Clark et al. [16] retrospectively reviewed 64
patients with T2 to T4 melanoma who underwent FDG-PET
for detection of occult metastases at their institution. All
patients underwent surgical excision of the primary lesion
and SLN dissection. None of the patients had clinically
suspected regional or distant metastases prior to FDG-
PET. Nineteen of 64 patients had positive SLN, and only
2 (11%) were identiﬁed on FDG-PET. Overall, FDG-PET
was not useful in predicting regional lymph node metastases
neither changed the clinical management in any of the pa-
tients. This study suggested no utility for FDG-PET in the
detection of occult metastases in patients at initial diagnosis
of melanoma. The authors recommended the omission of
FDG-PET imaging from preoperative evaluations for pa-
tients with melanoma; although they continued to suggest
FDG-PET evaluation for selected patients with signs and
symptoms of metastatic melanoma, they reported no role for
routine FDG-PET imaging for asymptomatic patients who
will be evaluated with SLN mapping. Further, it remains
clear that negative FDG-PET imaging cannot be considered
a viable substitute for SLNB [16].
In 2007, Kell et al. [17] examined the role of FDG-PET/
CT in patients undergoing SLNB for early-stage melanoma.
Patients presenting with primary melanoma without evi-
dence of either locoregional or systemic metastasis were con-
sidered candidates for SLNB. Selected patients underwent
preoperative FDG-PET/CT followed by deﬁnitive surgical
therapy including SLNB with regional lymphadenectomy,
where indicated. During a 12-month period, 83 patients
underwent SLNB for melanoma, of which 37 (45%) had
preoperative PET/CT. Thirteen (15.6%) patients were found
to have lymphatic metastasis at SLNB; among nine of these
patients who underwent FDG-PET/CT, only two PET scans
were suggestive of lymphatic metastasis (PPV: 24%, NPV:
76%). FDG-PET/CT revealed no unheralded metastatic
disease but identiﬁed a second occult malignancy in 4
(10.8%) patients undergoing therapy for melanoma. These
ﬁndings demonstrated that FDG-PET/CT is not a useful
adjuvant to lymphatic staging in patients with primary
melanoma without signs of lymphatic metastasis. SLNB is a
more sensitive tool in the detection of lymphatic metastasis.
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FDG-PET/CT may have some use in screening for unher-
alded occult primary malignancy, although the ﬁnancial and
quality of life implications of this have not been studied [17].
In the same year, Maubec et al. [18]p r o s p e c t i v e l yd e t e r -
mined the value of FDG-PET scanning in the detection of
regional metastasis in 25 patients referred for the treatment
of a primary melanoma thicker than 4mm. SLNB was
proposed for all the patients without a palpable regional
lymph node. FDG-PET identiﬁed 0/2 primary melanomas,
1/4 residual primary melanomas after limited excision, 0/6
lymph node basins with micrometastasis, 4/4 lymph node
basins with enlarged palpable lymph nodes, and 0 distant
metastasis. The sensitivity and speciﬁcity of FDG-PET for
microscopic lymph node disease in basins were, respectively,
0 and 92%. In the authors’ experience, it is not useful to
include FDG-PET in the initial workup of patients with
primary melanoma, even in patients with thick primary
melanomas (>4mm), and SLNB remains the technique of
choice for the most accurate initial staging [18].
In their study, Yancovitz et al. [19] examined the im-
pact of preoperative radiologic imaging (including FDG-
PET/CT), focusing on T1b to T3b melanoma patients
without clinical evidence of nodal or distant disease. One
hundred forty-two patients underwent SLNB, of whom 22
(15.5%) had positive results. Six of 22 patients with positive
SLNB had preoperative FDG-PET/CT, but only one PET/CT
study predicted the positive nodal basin. The study suggested
that asymptomatic patients with ≥4mm thick melanomas
do not warrant extensive radiologic work-up: imaging at
the time of initial diagnosis of T1b-T3b, clinically N0,
M0 melanoma was of low yield with a high false-positive
rate and did not lead to upstaging or changing the initial
surgical management. Therefore FDG-PET/CT imaging of
asymptomatic melanoma patients at the time of diagnosis
may not be warranted [19].
In 2008, Singh et al. [20] evaluated the role of preopera-
tive FDG-PET/CT, LS, and SLNB in 52 patients with AJCC
stage I or II melanoma. None of the patients had clinical
or radiological evidence of regional lymph node metastatic
disease. At least one SLN was identiﬁed in all patients.
Fourteen out of the 52 patients (27%) had at least one
involvedSLN.FDG-PET/CTwastruepositiveintwopatients
with a SLN greater than 1cm and false positive in two other
patients. In this study, FDG-PET/CT imaging demonstrated
very low sensitivity (14.3%) and PPV (50%) for localizing
the subclinical nodal metastases. The speciﬁcity, NPV, and
diagnosticaccuracywere94.7,75,and73%,respectively.Pre-
operative FDG-PET/CT imaging was not able to substitute
SLNB in patients with stage I or II melanoma [20].
Recently, Klode et al. [21] sought to clarify the role of
SLNBintheevaluationoftheinitialstagesof61patientswith
primary melanoma (AJCC stages I and II; Breslow thickness
>1mm) by comparing it directly with FDG-PET/CT eval-
uation. Metastatic SLNs were found in 14 patients (23%);
17 metastatic lymph nodes were detected overall, only one
of which was identiﬁed preoperatively using FDG-PET/CT.
Thus, PET/CT showed a sensitivity of 5.9% and an NPV
of 78%. The results of this study showed that initial-stage
FDG-PET/CT in patients with AJCC stage I or II melanoma
does not oﬀer any advantage over SLNB with respect to the
detection of local and regional metastases, because lymph
nodalmicrometastasescannotreliablybedetected.SLNB,on
the other hand, is a more sensitive procedure to diagnose
lymph nodal metastases of melanoma and continues to be
the criterion standard for the classiﬁcation and stratiﬁcation
for adjuvant therapy of patients with AJCC stage I or II
melanoma [21].
3. Remarks andConclusions
Overall, with a few exceptions [5], the results reported by
the studies in the literature are remarkably homogeneous in
pointing out the limitations of FDG-PET/CT for regional
lymph nodal staging in patients with cutaneous melanoma.
Indeed in patients with early-stage disease (AJCC stage I or
II, without regional lymph nodal or distant metastases), the
sensitivity of FDG-PET/CT is unacceptably low, with most
reported values ranging from 0% to 22% [4, 7, 9, 11, 12, 15,
16, 18, 20, 21]. Slightly higher- and yet too low-sensitivity
values (40%) were found only for intermediate/high-risk
melanoma patients [14], in whom metastatic adenopathy is
more likely.
In early-stage melanoma SLNB, typically performed fol-
lowing intraoperative lymphatic mapping is now the ref-
erence standard for regional lymph nodal staging when there
is no clinical evidence of regional nodal metastasis. The pro-
cedure is highly accurate for detecting occult lymph nodal
metastases, with a false-negative rate ≤5% for experienced
examiners. When there is clinical suspicion of metastatic
adenopathy, ultrasound of the nodal basin with ﬁne-needle
aspiration (FNA) or biopsy under ultrasound guidance may
otherwise be performed; if cytology is positive for malig-
nancy, the patient is sent directly to radical lymph node
dissection and SLNB is thus not necessary.
In the event of a negative sentinel lymph node biopsy,
the patient is considered to have clinical stage I or II disease
and no imaging is indicated: indeed, all imaging methods,
including US, CT, and FDG-PET or PET/CT, have limited
utility for the early stages of melanoma, with very low diag-
nostic yield and a burden of false-positive results leading to
unnecessary workup.
FDG-PET/CT has an extremely limited role, if any, in
microscopic nodal disease detection in patients with clinical
stages I and II disease, since normal-size lymph nodes may
contain micrometastases below the sensitivity threshold of
PET/CT. In this patient population, SLNB is much more
sensitive than PET/CT in discovering small lymph node
metastases. In conclusion, FDG-PET and FDG-PET/CT are
unsuitable for the evaluation of early regional lymphatic
tumour dissemination in patients with AJCC stage I or II
melanoma, and they should be limited to staging patients
with more advanced (AJCC stage III or IV) melanoma.
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